The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs) - 14/04/16
Abstract |
Background |
Combination therapies of excimer laser/light (EL) and various topical agents are widely used in the treatment of vitiligo.
Objective |
We sought to compare the efficacy of EL and topical agent combination therapy versus EL monotherapy for vitiligo.
Methods |
Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with topical agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure (<25% repigmentation); meta-analyses were performed when possible.
Results |
We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study).
Limitations |
These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation.
Conclusion |
Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy.
Le texte complet de cet article est disponible en PDF.Key words : excimer laser, laser, pimecrolimus, tacrolimus, topical calcineurin inhibitor, vitiligo
Abbreviations used : CI, EL, NB, RCT, RR, UV
Plan
Drs Bae and Hong contributed equally to this work. |
|
Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2014R1A1A1036218). |
|
Conflicts of interest: None declared. |
Vol 74 - N° 5
P. 907-915 - mai 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?